Search

Thelaziosis dog eyeworms

Have you heard of Thelaziosis? In Europe, some fruit flies host an emerging parasite known as “eyeworm”, an infestation which causes more or less severe conjunctivitis, sometimes leading to corneal ulcers and even blindness in dogs.

GPP: there is more than you see

Generalized Pustular Psoriasis is a rare neutrophilic skin condition. Watch an animation to learn about its recurrent nature and how it affects people

The power of our people

Diversity & Inclusion is an integral part of Boehringer Ingelheim's identity.

On the path to decarbonization: How we reduce our emissions

How our sites Fornovo and Paulínia became carbon-neutral and support our recently SBTi-validated 2030 goals

Sites Around the World

Enjoy the ride

Check out this video about the importance of reflecting on the ‘now’, and all the learning, development, and interactions that have led you there.

The Research Process

Therapeutics

The chronic nature of generalized pustular psoriasis

Understanding the impact of the physical and psychological symptoms of this chronic disease.

All hands-on deck to fight the ‘zombie’ rabies virus

We’re teaming up with communities and governments across Southeast Asia to fight rabies through vaccinations, education programs, and partnerships.

FDA-approves-nintedanib-in-SSc-ILD

FDA approves Ofev® as the first and only therapy in the U.S. to slow the rate of decline in pulmonary function in patients with systemic sclerosis-associated ILD

Pride Month 2023: Why belonging matters – to all of us

LGBTIQ+ community members and their allies share how we can create a welcoming and inclusive culture where everyone feels heard, accepted and appreciated.

PREVEXXION® RN: Marek’s disease vaccine available in EU UK

Boehringer Ingelheim is pleased to announce the launch of the next generation of Marek’s disease vaccines is now available in the EU.

Positive opinion Ingelvac CircoFLEX and Ingelvac PRRSFLEX EU

Boehringer Ingelheim receives positive opinion for the combined use of Ingelvac CircoFLEX® and Ingelvac PRRSFLEX EU® in the EU

Boehringer Ingelheim Ruminant Well-Being Awards 2020

The World Association for Buiatrics and Boehringer Ingelheim announce the Ruminant Well-Being Awards.

Nurjanahs Story

Nurjanah went from a sporty young woman to someone who no longer had the energy to do simple, everyday tasks. She was diagnosed with scleroderma.

Why is Diversity, Equity and Inclusion important to us?

emperor-preserved-heart-failure-full-data

Full results from EMPEROR-Preserved trial demonstrate significant improvement in heart failure outcomes in adults with preserved ejection fraction

Acquisition expands research in cancer immunology

Boehringer Ingelheim acquires Abexxa to develop novel cancer therapies by leveraging Abexxa’s unique technology and breakthrough antibody-based drugs.

EU approved Jardiance for type 2 diabetes in children

Jardiance® (empagliflozin) receives approval in the EU for the treatment of type 2 diabetes in children aged 10 years and above

European Commission decision for Pradaxa® in children with VTE

Pradaxa® (dabigatran etexilate) receives EU marketing authorization for the treatment and prevention of VTE in children from birth to less than 18 years of age

Performance Indicators

Performance indicators concerning Environment Health and Safety (EHS) are summarized here.

Boehringer acquires T3 Pharma

Boehringer Ingelheim expands immuno-oncology portfolio with the acquisition of bacterial cancer therapy specialist T3 Pharma

Targeting Tumor Stroma

Boehringer Ingelheim’s research approach in stromal biology may lead to new medicines that will change the face of cancer and give new hope to patients

Distributing medicine globally with pharmaceutical logistics

From Germany to Australia, here’s what it takes from operations and logistics to ensure patients get their medicine on time, every time.

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers